Which has preferable valuation and earnings, SNDL or BTMD?

biote has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SNDL $677.32M 0.49 -$11.29M -$0.03 N/A biote $192.22M 0.43 $27.05M $0.44 4.98

Is SNDL or BTMD more profitable?

biote has a net margin of 8.29% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets SNDL -1.19% -1.02% -0.85% biote 8.29% -25.72% 15.12%

Which has better valuation and earnings, BTMD or IRD?

biote has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.43 $27.05M $0.44 4.98 Opus Genetics $14.20M 20.70 -$49.59M -$1.33 N/A

Is BTMD or IRD more profitable?

biote has a net margin of 8.29% compared to Opus Genetics' net margin of -892.36%. biote's return on equity of -25.72% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Opus Genetics -892.36% -338.88% -191.21%

Does the media refer more to BTMD or IRD?

In the previous week, biote and biote both had 4 articles in the media. biote's average media sentiment score of 1.37 beat Opus Genetics' score of 0.31 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, IMRX or BTMD?

biote has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A biote $192.22M 0.43 $27.05M $0.44 4.98

Is IMRX or BTMD more profitable?

biote has a net margin of 8.29% compared to Immuneering's net margin of 0.00%. biote's return on equity of -25.72% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% biote 8.29% -25.72% 15.12%

Does the media favor IMRX or BTMD?

In the previous week, Immuneering had 2 more articles in the media than biote. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for biote. biote's average media sentiment score of 1.37 beat Immuneering's score of 0.93 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AMRN or BTMD?

biote has a consensus price target of $2.75, suggesting a potential upside of 25.57%. Given biote's higher probable upside, analysts plainly believe biote is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, AMRN or BTMD?

biote has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.41 -$38.80M -$0.65 N/A biote $192.22M 0.43 $27.05M $0.44 4.98

Is AMRN or BTMD more profitable?

biote has a net margin of 8.29% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% biote 8.29% -25.72% 15.12%

Does the media favor AMRN or BTMD?

In the previous week, Amarin and Amarin both had 4 articles in the media. biote's average media sentiment score of 1.37 beat Amarin's score of 0.43 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CLLS or BTMD?

biote has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 3.63 -$67.59M -$0.67 N/A biote $192.22M 0.43 $27.05M $0.44 4.98

Is CLLS or BTMD more profitable?

biote has a net margin of 8.29% compared to Cellectis' net margin of -89.51%. biote's return on equity of -25.72% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% biote 8.29% -25.72% 15.12%

biote (BTMD) Competitors

$2.19 -0.13 (-5.60%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.19 0.00 (0.00%)

As of 07/14/2026 06:02 PM Eastern

Compare

BTMD vs. SNDL, IRD, IMRX, AMRN, and CLLS

Should you buy biote stock or one of its competitors? MarketBeat compares biote with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with biote include SNDL (SNDL), Opus Genetics (IRD), Immuneering (IMRX), Amarin (AMRN), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.

How does biote compare to SNDL?

SNDL (NASDAQ:SNDL) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

biote has a net margin of 8.29% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
biote	8.29%	-25.72%	15.12%

SNDL has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, biote has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

In the previous week, biote had 3 more articles in the media than SNDL. MarketBeat recorded 4 mentions for biote and 1 mentions for SNDL. biote's average media sentiment score of 1.37 beat SNDL's score of 0.93 indicating that biote is being referred to more favorably in the news media.

Company	Overall Sentiment
SNDL	Positive
biote	Positive

biote has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.49	-$11.29M	-$0.03	N/A
biote	$192.22M	0.43	$27.05M	$0.44	4.98

SNDL currently has a consensus price target of $5.00, indicating a potential upside of 284.62%. biote has a consensus price target of $2.75, indicating a potential upside of 25.57%. Given SNDL's higher possible upside, equities analysts clearly believe SNDL is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

21.7% of biote shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

biote beats SNDL on 12 of the 16 factors compared between the two stocks.

How does biote compare to Opus Genetics?

biote (NASDAQ:BTMD) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

biote has a net margin of 8.29% compared to Opus Genetics' net margin of -892.36%. biote's return on equity of -25.72% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Opus Genetics	-892.36%	-338.88%	-191.21%

21.7% of biote shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 32.4% of biote shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

biote currently has a consensus target price of $2.75, suggesting a potential upside of 25.57%. Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 202.51%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

biote has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

biote has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.43	$27.05M	$0.44	4.98
Opus Genetics	$14.20M	20.70	-$49.59M	-$1.33	N/A

In the previous week, biote and biote both had 4 articles in the media. biote's average media sentiment score of 1.37 beat Opus Genetics' score of 0.31 indicating that biote is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

biote beats Opus Genetics on 11 of the 15 factors compared between the two stocks.

How does biote compare to Immuneering?

Immuneering (NASDAQ:IMRX) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

biote has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
biote	$192.22M	0.43	$27.05M	$0.44	4.98

Immuneering presently has a consensus target price of $16.57, suggesting a potential upside of 218.07%. biote has a consensus target price of $2.75, suggesting a potential upside of 25.57%. Given Immuneering's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immuneering is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Immuneering had 2 more articles in the media than biote. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for biote. biote's average media sentiment score of 1.37 beat Immuneering's score of 0.93 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.7% of Immuneering shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immuneering has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, biote has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

biote has a net margin of 8.29% compared to Immuneering's net margin of 0.00%. biote's return on equity of -25.72% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
biote	8.29%	-25.72%	15.12%

Summary

biote beats Immuneering on 10 of the 15 factors compared between the two stocks.

How does biote compare to Amarin?

Amarin (NASDAQ:AMRN) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Amarin and Amarin both had 4 articles in the media. biote's average media sentiment score of 1.37 beat Amarin's score of 0.43 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Amarin shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

biote has a consensus price target of $2.75, suggesting a potential upside of 25.57%. Given biote's higher probable upside, analysts plainly believe biote is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 8.29% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
biote	8.29%	-25.72%	15.12%

Amarin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, biote has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

biote has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.41	-$38.80M	-$0.65	N/A
biote	$192.22M	0.43	$27.05M	$0.44	4.98

Summary

biote beats Amarin on 10 of the 14 factors compared between the two stocks.

How does biote compare to Cellectis?

Cellectis (NASDAQ:CLLS) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

biote has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.63	-$67.59M	-$0.67	N/A
biote	$192.22M	0.43	$27.05M	$0.44	4.98

biote has a net margin of 8.29% compared to Cellectis' net margin of -89.51%. biote's return on equity of -25.72% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
biote	8.29%	-25.72%	15.12%

63.9% of Cellectis shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cellectis currently has a consensus target price of $7.00, suggesting a potential upside of 143.06%. biote has a consensus target price of $2.75, suggesting a potential upside of 25.57%. Given Cellectis' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectis is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, biote had 3 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for biote and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat biote's score of 1.37 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Very Positive
biote	Positive

Cellectis has a beta of 2.88, suggesting that its stock price is 188% more volatile than the broader market. Comparatively, biote has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Summary

biote beats Cellectis on 9 of the 16 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$87.19M	$8.67B	$6.85B	$12.44B
Dividend Yield	N/A	2.54%	2.68%	8.43%
P/E Ratio	4.98	15.65	27.04	24.38
Price / Sales	0.43	6.99	524.25	92.59
Price / Cash	4.00	18.09	48.59	59.36
Price / Book	-1.56	3.56	10.80	6.33
Net Income	$27.05M	$228.19M	$3.59B	$331.02M
7 Day Performance	-3.10%	-1.41%	-1.46%	-0.33%
1 Month Performance	-2.67%	-2.08%	2.82%	-1.29%
1 Year Performance	-44.42%	2.26%	28.59%	21.30%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	4.6813 of 5 stars	$2.19 -5.6%	$2.75 +25.6%	-45.8%	$87.19M	$192.22M	4.98	194	News Coverage Positive News Short Interest Decrease
SNDL SNDL	3.903 of 5 stars	$1.30 flat	$5.00 +284.6%	-17.7%	$334.62M	$677.32M	N/A	2,751	News Coverage
IRD Opus Genetics	2.8586 of 5 stars	$4.05 -0.5%	$10.77 +165.9%	+220.7%	$334.41M	$14.20M	N/A	14
IMRX Immuneering	3.1043 of 5 stars	$5.10 -0.8%	$16.50 +223.5%	+24.9%	$329.97M	N/A	N/A	60	Analyst Upgrade
AMRN Amarin	1.803 of 5 stars	$15.46 -1.7%	N/A	-10.7%	$324.20M	$213.65M	N/A	360	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors